XOMA Royalty Corp Files 8-K/A Amendment
Ticker: XOMAP · Form: 8-K/A · Filed: Feb 11, 2025 · CIK: 791908
| Field | Detail |
|---|---|
| Company | Xoma Royalty Corp (XOMAP) |
| Form Type | 8-K/A |
| Filed Date | Feb 11, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0075, $0.05, $20 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, financial-statements, exhibits
TL;DR
XOMA Royalty Corp filed an amendment to its 8-K, updating financial statements and exhibits as of Nov 26, 2024.
AI Summary
XOMA Royalty Corp filed an amendment (8-K/A) on February 11, 2025, to its report originally dated November 26, 2024. This amendment primarily concerns financial statements and exhibits related to the company's reporting period ending November 26, 2024. The filing details the company's common stock and preferred stock, including Series A Cumulative Perpetual Preferred Stock and Series B Cumulative Perpetual Preferred Stock.
Why It Matters
This amendment provides updated financial information and exhibits, which are crucial for investors to assess the company's financial health and any changes in its capital structure.
Risk Assessment
Risk Level: low — This filing is an amendment to a previous report, primarily containing financial statements and exhibits, and does not appear to disclose new material risks.
Key Players & Entities
- XOMA Royalty Corp (company) — Registrant
- November 26, 2024 (date) — Earliest event reported date
- February 11, 2025 (date) — Filing date of amendment
- 8.625% Series A Cumulative Perpetual Preferred Stock (security) — Preferred stock mentioned
- 8.375% Series B Cumulative Perpetual Preferred Stock (security) — Preferred stock mentioned
FAQ
What is the purpose of this 8-K/A filing?
This 8-K/A filing serves as an amendment to a previously filed 8-K report, primarily to update financial statements and exhibits.
What is the earliest event date reported in this filing?
The earliest event date reported is November 26, 2024.
When was this amendment filed with the SEC?
This amendment was filed with the SEC on February 11, 2025.
What types of securities are specifically mentioned in the filing details?
The filing details mention common stock, Series A Cumulative Perpetual Preferred Stock, and Series B Cumulative Perpetual Preferred Stock.
What is the SIC code for XOMA Royalty Corp?
The Standard Industrial Classification (SIC) code for XOMA Royalty Corp is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 806 words · 3 min read · ~3 pages · Grade level 11.2 · Accepted 2025-02-11 08:26:08
Key Financial Figures
- $0.0075 — ange on which registered Common Stock, $0.0075 par value XOMA The Nasdaq Global Ma
- $0.05 — ve Perpetual Preferred Stock, par value $0.05 per share XOMAP The Nasdaq Global M
- $20 million — of November 26, 2024 in exchange for a $20 million cash payment at closing. The Company i
Filing Documents
- d935049d8ka.htm (8-K/A) — 33KB
- d935049dex231.htm (EX-23.1) — 2KB
- d935049dex992.htm (EX-99.2) — 114KB
- d935049dex993.htm (EX-99.3) — 99KB
- d935049dex994.htm (EX-99.4) — 157KB
- 0001193125-25-024024.txt ( ) — 625KB
- xoma-20241126.xsd (EX-101.SCH) — 4KB
- xoma-20241126_def.xml (EX-101.DEF) — 14KB
- xoma-20241126_lab.xml (EX-101.LAB) — 25KB
- xoma-20241126_pre.xml (EX-101.PRE) — 16KB
- d935049d8ka_htm.xml (XML) — 9KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (a) Financial Statements of Businesses Acquired The financial statements of Pulmokine as of and for the year ended December 31, 2023 (audited) and as of and for the nine months ended September 30, 2024 (unaudited) are filed as Exhibit 99.2 and Exhibit 99.3 to this Amendment. (b) Pro Forma Financial Information The unaudited pro forma condensed combined balance sheet as of September 30, 2024, the unaudited pro forma condensed combined statement of operations for the nine months ended September 30, 2024, the unaudited pro forma combined statement of operations for the year ended December 31, 2023, and notes to the unaudited pro forma condensed combined financial information of the Company, all giving effect to the acquisition, are filed as Exhibit 99.4 to this Amendment and incorporated herein by reference. (d) Exhibits Exhibit No. Description 23.1 Consent of Rosenberg Rich Baker Berman, P.A., Independent Certified Public Accountants. 99.1+ Press Release issued by XOMA Corporation on December 2, 2024 (incorporated herein by reference to Exhibit 99.1 to the Form 8-K filed by XOMA Royalty Corporation on December 2, 2024). 99.2 Audited Financial Statements of Pulmokine, Inc. as of and for the Year Ended December 31, 2023. 99.3 Unaudited Condensed Financial Statements of Pulmokine, Inc. as of and for the Nine Months Ended September 30, 2024. 99.4 Unaudited Pro Forma Condensed Combined Financial Information of XOMA Royalty Corporation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). + Previously Filed
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XOMA ROYALTY CORPORATION Date: February 11, 2025 By: /s/ Owen Hughes Name: Owen Hughes Title: Chief Executive Officer